A Systematic Approach to the Development of Cilostazol Nanosuspension by Liquid Antisolvent Precipitation (LASP) and Its Combination with Ultrasound

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Nov 27

PMID 34830298

Citations 2

Authors

Emilia Jakubowska

Bartlomiej Milanowski

Janina Lulek

Affiliations

Soon will be listed here.

Abstract

Nanosizing is an approach to improve the dissolution rate of poorly soluble drugs. The first aim of this work was to develop nanosuspension of cilostazol with liquid antisolvent precipitation (LASP) and its combination with ultrasound. Second, to systematically study the effect of bottom-up processing factors on precipitated particles' size and identify the optimal settings for the best reduction. After solvent and stabilizer screening, in-depth process characterization and optimization was performed using Design of Experiments. The work discusses the influence of critical factors found with statistical analysis: feed concentration, stabilizer amount, stirring speed and ultrasound energy governed by time and amplitude. LASP alone only generated particle size of a few microns, but combination with ultrasound was successful in nanosizing (d10 = 0.06, d50 = 0.33, d90 = 1.45 µm). Micro- and nanosuspension's stability, particle morphology and solid state were studied. Nanosuspension displayed higher apparent solubility than equilibrium and superior dissolution rate over coarse cilostazol and microsuspension. A bottom-up method of precipitation-sonication was demonstrated to be a successful approach to improve the dissolution characteristics of poorly soluble, BCS class II drug cilostazol by reducing its particle size below micron scale, while retaining nanosuspension stability and unchanged crystalline form.

Citing Articles

Development of a Carvedilol-Loaded Solid Self-Nanoemulsifying System with Increased Solubility and Bioavailability Using Mesoporous Silica Nanoparticles.

Jang H, Kim N, Jin S Int J Mol Sci. 2025; 26(4).

PMID: 40004060 PMC: 11855893. DOI: 10.3390/ijms26041592.

Drug nanocrystals: Surface engineering and its applications in targeted delivery.

Lhaglham P, Jiramonai L, Jia Y, Huang B, Huang Y, Gao X iScience. 2024; 27(11):111185.

PMID: 39555405 PMC: 11564948. DOI: 10.1016/j.isci.2024.111185.

Targeted Delivery to Dying Cells Through P-Selectin-PSGL-1 Axis: A Promising Strategy for Enhanced Drug Efficacy in Liver Injury Models.

Lien T, Sun D, Chang H Cells. 2024; 13(21.

PMID: 39513885 PMC: 11545035. DOI: 10.3390/cells13211778.

References

Miao X, Sun C, Jiang T, Zheng L, Wang T, Wang S . Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol. J Pharm Pharm Sci. 2011; 14(2):196-214. DOI: 10.18433/j3pw2w. View

Mustapha O, Kim K, Shafique S, Kim D, Jin S, Seo Y . Comparison of three different types of cilostazol-loaded solid dispersion: Physicochemical characterization and pharmacokinetics in rats. Colloids Surf B Biointerfaces. 2017; 154:89-95. DOI: 10.1016/j.colsurfb.2017.03.017. View

Sun W, Mao S, Shi Y, Li L, Fang L . Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. J Pharm Sci. 2011; 100(8):3365-3373. DOI: 10.1002/jps.22587. View

Jain S, Reddy V, Arora S, Patel K . Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability. Drug Deliv Transl Res. 2016; 6(5):498-510. DOI: 10.1007/s13346-016-0297-8. View

Tran T, Tran P, Nguyen M, My Tran K, Pham M, Tran P . Amorphous isradipine nanosuspension by the sonoprecipitation method. Int J Pharm. 2014; 474(1-2):146-50. DOI: 10.1016/j.ijpharm.2014.08.017. View

Sun J, Wang F, Sui Y, She Z, Zhai W, Wang C . Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q₁₀ as naked nanocrystals. Int J Nanomedicine. 2012; 7:5733-44. PMC: 3500035. DOI: 10.2147/IJN.S34365. View

Sinha B, Muller R, Moschwitzer J . Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm. 2013; 453(1):126-41. DOI: 10.1016/j.ijpharm.2013.01.019. View

Sai Gouthami K, Kumar D, Thipparaboina R, Chavan R, Shastri N . Can crystal engineering be as beneficial as micronisation and overcome its pitfalls?: A case study with cilostazol. Int J Pharm. 2015; 491(1-2):26-34. DOI: 10.1016/j.ijpharm.2015.06.009. View

Iurian S, Tomuta I, Rus L, Achim M, Leucuta S . Optimization of the sonication process for meloxicam nanocrystals preparation. Clujul Med. 2015; 88(3):366-72. PMC: 4632897. DOI: 10.15386/cjmed-445. View

10.

Singare D, Marella S, Gowthamrajan K, Kulkarni G, Vooturi R, Rao P . Optimization of formulation and process variable of nanosuspension: An industrial perspective. Int J Pharm. 2010; 402(1-2):213-20. DOI: 10.1016/j.ijpharm.2010.09.041. View

11.

Kassem M, ElMeshad A, Fares A . Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design. AAPS PharmSciTech. 2016; 18(4):983-996. DOI: 10.1208/s12249-016-0604-1. View

12.

Rangaraj N, Pailla S, Chowta P, Sampathi S . Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability. AAPS PharmSciTech. 2019; 20(8):326. DOI: 10.1208/s12249-019-1524-7. View

13.

DAddio S, Prudhomme R . Controlling drug nanoparticle formation by rapid precipitation. Adv Drug Deliv Rev. 2011; 63(6):417-26. DOI: 10.1016/j.addr.2011.04.005. View

14.

Motta N, Autran L, Brazao S, de Oliveira Lopes R, Scaramello C, Lima G . Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target. Int Immunopharmacol. 2021; 92:107336. PMC: 7768212. DOI: 10.1016/j.intimp.2020.107336. View

15.

Dalvi S, Yadav M . Effect of ultrasound and stabilizers on nucleation kinetics of curcumin during liquid antisolvent precipitation. Ultrason Sonochem. 2014; 24:114-22. DOI: 10.1016/j.ultsonch.2014.11.016. View

16.

Peltonen L, Strachan C . Understanding Critical Quality Attributes for Nanocrystals from Preparation to Delivery. Molecules. 2015; 20(12):22286-300. PMC: 6332140. DOI: 10.3390/molecules201219851. View

17.

Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C . DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010; 12(3):263-71. PMC: 2895453. DOI: 10.1208/s12248-010-9185-1. View

18.

Sander J, Zeiger B, Suslick K . Sonocrystallization and sonofragmentation. Ultrason Sonochem. 2014; 21(6):1908-15. DOI: 10.1016/j.ultsonch.2014.02.005. View

19.

Verma S, Gokhale R, Burgess D . A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm. 2009; 380(1-2):216-22. DOI: 10.1016/j.ijpharm.2009.07.005. View

20.

Verma S, Rudraraju V . Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution Rate for Amorphous Solid Dispersion of a Poorly Soluble Drug. AAPS PharmSciTech. 2015; 16(5):1079-90. PMC: 4674650. DOI: 10.1208/s12249-014-0281-x. View